HighLife SAS, a medtech company focused on the development of a unique Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from mitral regurgitation, announced today that several presentations will be featured during EuroPCR 2021 (May 18-20, 2021).
Recorded interviews with Dr Didier Tchétché, interventional cardiologist and Head of the Structural Heart disease program at Clinique Pasteur, in Toulouse, France and also with Prof Wolfgang Rottbauer, Director at the Department of Cardiology at Ulm University in Germany, will be made available today on the congress’ EuroPCR website.
A link to the recorded presentations will also be available on the HighLife website in the physician section here and LinkedIn page here.
Dr Tchétché is presenting the interim data of the first 20 patients in HighLife’s ongoing clinical studies. He is also providing an outlook on its upcoming clinical study with the new HighLife Clarity valve in patients who are at high risk for LVOT obstruction.
Prof Rottbauer is presenting the HighLife procedure step by step with a case example and provides commentary regarding his recent personal experience with the technology.
These recorded interviews follow two earlier presentations on the HighLife mitral replacement technology over the last few weeks. Prof Rüdiger Lange, Director of Cardiac Surgery in the German Heart Center in Munich, Germany presented on HighLife’s TSMVR among other technologies at the 3rd Chinese Summit on Mitral Valves Interventional Therapies on April 16. Also, Dr Nicolo Piazza, interventional cardiologist at McGill University in Montreal, Canada presented at China Interventional Therapeutics (CIT) on May 7.
Dr Tchétché and Prof Rottbauer are currently investigators in HighLife’s clinical study enrolling in Europe and Australia (NCT04029363). Prof Lange’s hospital is a participating site for the same study. Dr Piazza is the primary proctor for HighLife’s clinical technology.
HighLife SAS was established in 2010 and is headquartered in Paris, France, with a facility in Irvine, CA (USA). It is focused on the development of a novel trans-septal mitral replacement system for treating mitral regurgitation. The technology aims at a beating heart procedure, reducing trauma to the patients through a purely endovascular approach.
Caution: The HighLife Trans-Septal Mitral Valve (TSMV) is an investigational device and not available for sale.
For more information please contact:
Tel : +33 (0)1 72 32 21 15